Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 204

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 204
---
iences, Inc.  |  Q3 2025 Form 10-Q  |  29

NOTE 15—CONTINGENT CONSIDERATION CHARGES (GAINS), ACQUISITION-RELATED EXPENSES, RESTRUCTURING AND OTHER

Contingent consideration charges (gains), acquisition-related expenses, restructuring and other for the nine months ended September 30, 2025 and 2024 summarized below (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Contingent consideration charges (gains)$625 $(3,244)$(2,407)$(5,541)Restructuring charges3,728 1,193 3,728 7,724 Acquisition-related expenses(280)285 2,222 689 Legal settlement— — 7,000 — Legal judgment(23,148)— (23,148)— Impairment of acquired IPR&D25,866 — 25,866 — Total contingent consideration charges (gains), acquisition-related expenses, restructuring and other$6,791 $(1,766)$13,261 $2,872 Flexion Acquisition Contingent ConsiderationThe Company recognized charges of $0.6 million and gains of $2.4 million related to contingent consideration arising from the Flexion Acquisition during the three and nine months ended September 30, 2025, respectively. The Company recognized gains of $3.2 million and $5.5 million related to contingent consideration during the three and nine months ended September 30, 2024, respectively. See Note 10, Financial Instruments, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration and more information regarding the changes in fair value.2025 Restructuring ChargesIn July 2025, as a result of improving manufacturing efficiencies for EXPAREL, the Company instituted a reduction in force at its Science Center Campus in San Diego, California. The Company’s enhanced efficiencies are the result of its multi-year investment in two large-scale 200+ liter EXPAREL batch manufacturing suites located in San Diego and Swindon, U.K., which commenced commercial production in 2024 and 2021, respectively.These two large-scale manufacturing suites are capable of producing bulk EXPAREL volumes that are approximately four-fold greater than the Company’s 45-liter batch manufacturing process.